166 related articles for article (PubMed ID: 37288326)
21. Meta-analysis: rapid infliximab infusions are safe.
Neef HC; Riebschleger MP; Adler J
Aliment Pharmacol Ther; 2013 Aug; 38(4):365-76. PubMed ID: 23815183
[TBL] [Abstract][Full Text] [Related]
22. Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study.
Viola A; Costantino G; Privitera AC; Bossa F; Lauria A; Grossi L; Principi MB; Della Valle N; Cappello M
World J Gastrointest Pharmacol Ther; 2017 May; 8(2):131-136. PubMed ID: 28533923
[TBL] [Abstract][Full Text] [Related]
23. Rapid Infliximab Infusion in Children with Inflammatory Bowel Disease: A Multicenter North American Experience.
El-Matary W; Dykes DMH; Bauman L; Elkadri A; Carroll MW; Izaguirre MR; deBruyn J; Samson CM; Crim AM; Ali S; Grossman A
Inflamm Bowel Dis; 2017 Dec; 23(12):2104-2108. PubMed ID: 29140940
[TBL] [Abstract][Full Text] [Related]
24. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.
Van Assche G; Vermeire S; Noman M; Amant C; Weyts E; Vleminckx A; Vermeyen MJ; Rutgeerts P
J Crohns Colitis; 2010 Sep; 4(3):329-33. PubMed ID: 21122522
[TBL] [Abstract][Full Text] [Related]
25. A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study.
Lee TW; Singh R; Fedorak RN
Aliment Pharmacol Ther; 2011 Jul; 34(2):181-7. PubMed ID: 21615434
[TBL] [Abstract][Full Text] [Related]
26. Infliximab infusion time in patients with inflammatory bowel diseases: is longer really safer?
Belhassan M; Zeitoun JD; Lefevre JH; Charachon A; Amiot A; Le Baleur Y; Sobhani I; Delchier JC
Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):189-92. PubMed ID: 23246140
[TBL] [Abstract][Full Text] [Related]
27. Impact of rapid infliximab infusions on access at a large academic tertiary medical center.
Pusateri A; Hatcher A; Patel N; Lehman J; Hinton A; Afzali A
Am J Health Syst Pharm; 2021 Nov; 78(22):2046-2052. PubMed ID: 34050749
[TBL] [Abstract][Full Text] [Related]
28. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre.
Wee JS; Petrof G; Jackson K; Barker JN; Smith CH
Br J Dermatol; 2012 Aug; 167(2):411-6. PubMed ID: 22404545
[TBL] [Abstract][Full Text] [Related]
29. Infliximab in inflammatory bowel disease. Is premedication necessary?
Nuñez F P; Quera R; Simian D; Flores L; Figueroa C; Ibañez P; Kronberg U; Lubascher J; Pizarro G
Gastroenterol Hepatol; 2021 May; 44(5):321-329. PubMed ID: 33386199
[TBL] [Abstract][Full Text] [Related]
30. Rapid Infliximab Infusion in Children: A Multicenter Retrospective Cohort Study.
Lev-Tzion R; Assa A; Yerushalmi B; Lahad A; Friedman M; Ledder O; Turner D
J Pediatr Gastroenterol Nutr; 2017 Nov; 65(5):e101-e103. PubMed ID: 29064928
[TBL] [Abstract][Full Text] [Related]
31. Does infliximab short infusion have a beneficial impact on the quality of life in patients with inflammatory bowel diseases? A single centre prospective evaluation.
Principi M; Losurdo G; La Fortezza RF; Lopolito P; Lovero R; Grillo S; Bringiotti R; Ierardi E; Di Leo A
J Gastrointestin Liver Dis; 2015 Jun; 24(2):165-70. PubMed ID: 26114175
[TBL] [Abstract][Full Text] [Related]
32. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
Shergy WJ; Isern RA; Cooley DA; Harshbarger JL; Huffstutter JE; Hughes GM; Spencer-Smith EA; Goldman AL; Roth SH; Toder JS; Warner D; Quinn A; Keenan GF; Schaible TF;
J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
[TBL] [Abstract][Full Text] [Related]
33. Safety of infliximab in children with IBD: the experience of an academic center in WV.
Northcutt M; Al-Subu A; Bella B; Elitsur Y
W V Med J; 2014; 110(3):26-9. PubMed ID: 24984403
[TBL] [Abstract][Full Text] [Related]
34. Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients-a case-control study.
van Wassenaer EA; Meester VL; Kindermann A; Koot BGP; Benninga MA; de Meij TGJ
Eur J Clin Pharmacol; 2019 Oct; 75(10):1445-1450. PubMed ID: 31332475
[TBL] [Abstract][Full Text] [Related]
35. Frequency of Severe Infusion Reactions Associated With Outpatient Infusion of Infliximab Without Premedications.
Hutsell SQ; Wu M; Park KT
J Pediatr Gastroenterol Nutr; 2017 Oct; 65(4):430-431. PubMed ID: 28937551
[TBL] [Abstract][Full Text] [Related]
36. Safety of Rapid Infliximab Biosimilar Infusions in Patients With Inflammatory Bowel Disease.
Kim JY; Bhat S
Ann Pharmacother; 2022 Mar; 56(3):280-284. PubMed ID: 34192881
[TBL] [Abstract][Full Text] [Related]
37. Natalizumab for induction of remission in Crohn's disease.
Nelson SM; Nguyen TM; McDonald JW; MacDonald JK
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006097. PubMed ID: 30068022
[TBL] [Abstract][Full Text] [Related]
38. Adverse Events and Compliance Among Inflammatory Bowel Disease Patients Treated With Home- vs Office-Based Biologic Infusions.
Schmoyer CJ; Sun K; Zack J; Kumar P; Shivashankar R
Inflamm Bowel Dis; 2023 Oct; ():. PubMed ID: 37819840
[TBL] [Abstract][Full Text] [Related]
39. Rapid Infliximab Infusion in the Pediatric Population.
Munsel EJ; Bryan PJ; Binstadt BA; Bullock D; Correll CK; Downs EM; Hobday PM; Larson-Nath C; Sudel B; Vehe RK
J Pediatr Pharmacol Ther; 2020; 25(8):705-708. PubMed ID: 33214781
[TBL] [Abstract][Full Text] [Related]
40. Costs of providing infusion therapy for patients with inflammatory bowel disease in a hospital-based infusion center setting.
Afzali A; Ogden K; Friedman ML; Chao J; Wang A
J Med Econ; 2017 Apr; 20(4):409-422. PubMed ID: 28112566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
